​

UroGen Pharma Ownership | Who Owns UroGen Pharma?

OverviewForecastRevenueFinancialsChartTranscripts

UroGen Pharma Ownership Summary

UroGen Pharma is owned by 87.67% institutional investors, 3.48% insiders, and 8.85% retail investors. Rtw investments, lp is the largest institutional shareholder, holding 9.23% of URGN shares. BioPharma Credit Ord is the top mutual fund, with 10.18% of its assets in UroGen Pharma shares.

URGN Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockUroGen Pharma87.67%3.48%8.85%
SectorHealthcare Stocks 244.37%12.11%-156.48%
IndustryBiotech Stocks 379.01%11.75%-290.76%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Rtw investments, lp4.54M9.23%$81.70M
Blackrock2.19M6.57%$36.81M
Cowen and company2.10M6.29%$35.23M
Blackrock funding, inc. /de2.85M5.78%$51.16M
Morgan stanley2.56M5.20%$46.03M
Kynam capital management, lp2.25M4.57%$40.41M
Jefferies financial group2.20M4.47%$39.55M
Acorn capital advisors1.67M3.40%$30.09M
Sg americas securities1.66M3.37%$29.81M
American century companies1.64M3.33%$29.44M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Acorn capital advisors1.67M8.55%$30.09M
Superstring capital management lp387.37K4.98%$6.96M
Opaleye management1.43M3.39%$25.71M
Silverarc capital management1.50M2.76%$27.02M
Kynam capital management, lp2.25M2.49%$40.41M
Bioimpact capital943.80K1.31%$16.97M
Boxer capital management500.00K1.18%$8.99M
Cowen and company2.10M0.97%$35.23M
Privium fund management b.v.238.12K0.89%$4.28M
Rtw investments, lp4.54M0.81%$81.70M

Top Buyers

HolderShares% AssetsChange
Kynam capital management, lp2.25M2.49%2.25M
Opaleye management1.43M3.39%1.16M
Soleus capital management727.00K0.53%577.00K
Frontier capital management1.31M0.24%532.49K
Blackrock2.19M0.00%477.14K

Top Sellers

HolderShares% AssetsChange
Ra capital management---3.21M
Toronto dominion bank---2.62M
Paradigm biocapital advisors lp---1.70M
Adage capital partners gp---830.00K
Healthcare of ontario pension plan trust fund387.07K0.01%-738.03K

New Positions

HolderShares% AssetsChangeValue
Two sigma advisers, lp111.60K0.00%111.60K$2.23M
Swiss national bank77.80K0.00%77.80K$1.40M
State of wisconsin investment board32.12K0.00%32.12K$577.45K
Vanguard fiduciary trust31.56K0.00%31.56K$567.43K
Vanguard asset management26.00K0.00%26.00K$467.55K

Sold Out

HolderChange
Jpl wealth management-1.00
Nelson, van denburg & campbell wealth management group-4.00
Clearstead advisors-9.00
Srs capital advisors-14.00
Us bancorp \de\-17.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 202619911.17%44,166,157-4.90%871.02%10322.62%5412.50%
Mar 31, 202670-60.00%6,164,059-85.90%120.15%34-57.50%15-72.73%
Dec 31, 202599-42.11%18,257,389-58.48%370.45%43-49.41%32-30.43%
Sep 30, 20251624.52%41,959,88915.94%871.53%822.50%457.14%
Jun 30, 202516313.99%39,787,671-4.46%831.08%8431.25%43-12.24%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
BioPharma Credit Ord4.69M10.18%4.69M
RTW Biotech Opportunities Ord1.36M2.90%1.36M
UBS (Lux) Digital Health Equity SB USD1.32M2.86%-
UBS Lux Dgtl Hlth Eq Fd seeding P acc1.25M2.71%-
iShares Russell 2000 ETF1.08M2.22%-19.30K
American Century U.S. Small Cap Growth874.98K1.80%-
American Century Small Cap Growth Inv874.98K1.80%-
International Biotechnology Ord427.15K0.93%-34.85K
Fidelity Small Cap Index399.81K0.82%2.23K
Biotech Growth Ord384.73K0.79%-202.30K

Recent Insider Transactions

DateNameRoleActivityValue
Aug 20, 2026Schoenberg Mark Chief Medical OfficerSell$2.85M
Jul 09, 2026Schoenberg Mark Chief Medical OfficerSell$400.00K
Jun 22, 2026Schoenberg Mark Chief Medical OfficerSell$350.10K
Jun 08, 2026Schoenberg Mark Chief Medical OfficerSell$142.56K
May 08, 2026Schoenberg Mark Chief Medical OfficerSell$300.00K

Insider Transactions Trends

DateBuySell
2026 Q3-2
2026 Q2-3
2026 Q1-6
2025 Q4-2
2025 Q3-5

URGN Ownership FAQ

Who Owns UroGen Pharma?

UroGen Pharma shareholders are primarily institutional investors at 87.67%, followed by 3.48% insiders and 8.85% retail investors. The average institutional ownership in UroGen Pharma's industry, Biotech Stocks , is 379.01%, which UroGen Pharma falls below.

Who owns the most shares of UroGen Pharma?

UroGen Pharma’s largest shareholders are Rtw investments, lp (4.54M shares, 9.23%), Blackrock (2.19M shares, 6.57%), and Cowen and company (2.1M shares, 6.29%). Together, they hold 22.09% of UroGen Pharma’s total shares outstanding.

Does Blackrock own UroGen Pharma?

Yes, BlackRock owns 6.57% of UroGen Pharma, totaling 2.19M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 36.81M$. In the last quarter, BlackRock increased its holdings by 477.14K shares, a 27.79% change.

Who is UroGen Pharma’s biggest shareholder by percentage of total assets invested?

Acorn capital advisors is UroGen Pharma’s biggest shareholder by percentage of total assets invested, with 8.55% of its assets in 1.67M UroGen Pharma shares, valued at 30.09M$.

Who is the top mutual fund holder of UroGen Pharma shares?

BioPharma Credit Ord is the top mutual fund holder of UroGen Pharma shares, with 10.18% of its total shares outstanding invested in 4.69M UroGen Pharma shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools